[177Lu]Lu-PSMA治疗期间肿瘤生长的数学建模:对治疗优化的启示
该研究建立数学模型描述[177Lu]Lu-PSMA治疗期间肿瘤生长,在固定总活度44.4 GBq、间隔6周条件下比较标准6周期方案与不同周期方案。以肿瘤质量最低点为优化指标,小肿瘤负荷(如<4 g)对周期数不敏感,较大肿瘤(如7 g)减少周期数效果更好。基于模型模拟,推荐1-2周期方案以获得更好结局。
要点
- 总活度44.4 GBq、间隔6周时,6周期与1-2周期方案对<4 g肿瘤效果相当。
- 7 g肿瘤中,5、4、3和1-2周期方案分别比6周期方案有效24%、50%、76%和84%。
- 各分次方案肾脏生物有效剂量均在耐受范围内(<40 Gy)。
核心结论
- 基于模型推导的模拟,推荐采用1-2周期方案为接受[177Lu]Lu-PSMA治疗的患者获得更好结局。
研究设计与样本
- 开发数学模型描述[177Lu]Lu-PSMA治疗期间肿瘤生长,采用文献报道的患者药代动力学中位数获得剂量率随时间变化。
- 模型纳入Gompertz肿瘤生长模型和线性二次模型描述辐射诱导细胞杀伤对肿瘤生长的影响。
- 在固定总活度44.4 GBq的[177Lu]Lu-PSMA-617和6周周期间隔下,比较标准6周期方案与不同治疗方案在已发表肿瘤质量分布中的疗效。
- 考察的方案为第一周期给予7.4 GBq、第二周期给予剩余活度37 GBq(1-2周期治疗)。
主要发现
- 以肿瘤质量最低点为优化指标时,较低肿瘤负荷(如<4 g)对周期数不敏感,6周期治疗与1-2周期治疗等效。
- 对于较大肿瘤质量,较少周期数获得更好结果。
- 对于7 g肿瘤,5周期、4周期、3周期和1-2周期方案分别比6周期方案有效24%、50%、76%和84%。
- 肾脏、腮腺、泪腺和红骨髓的吸收剂量分别为23、16、70和1 Gy。
- 在所有分次方案中,肾脏的生物有效剂量均在耐受范围内(<40 Gy)。
关键数值与推荐
- 固定总活度为44.4 GBq的[177Lu]Lu-PSMA-617,周期间隔为6周。
- 1-2周期方案为第一周期给予7.4 GBq、第二周期给予剩余37 GBq。
- 肾脏生物有效剂量耐受阈值为<40 Gy。
- 肾脏、腮腺、泪腺和红骨髓的吸收剂量分别为23、16、70和1 Gy。
临床怎么用
- 基于模型推导的模拟,推荐采用1-2周期方案为接受[177Lu]Lu-PSMA治疗的患者获得更好结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment regimen for [177Lu]Lu-prostate-specific membrane antigen (PSMA) 617 therapy follows that of chemotherapy: 6 administrations of a fixed activity, each separated by 6 wk. Mathematic modeling can be used to test the hypothesis that the current treatment regimen for a radiopharmaceutical modality is suboptimal. Methods: A mathematic model was developed to describe tumor growth during [177Lu]Lu-PSMA therapy. The model examined alternative treatment schedules to maximize tumor mass reduction while still maintaining an acceptable biologically effective dose to kidneys. Median patients' pharmacokinetics from literature reports were used to obtain the dose rate over time. The model incorporates the Gompertz tumor growth and linear quadratic models to describe the effect of radiation-induced cell kill on tumor growth. For a fixed total activity of 44.4 GBq of [177Lu]Lu-PSMA-617 and a 6-wk interval between cycles, the efficacy of the standard fractionation (6-cycle) treatment schedule was compared with different treatment regimens for a distribution of published tumor masses. A treatment schedule whereby 7.4 GBq are administered in the first cycle, and the remaining activity (37 GBq) in the second cycle (1-2-cycle treatment), was examined. Results: When tumor mass nadir was used as the optimization metric, a lower tumor burden (e.g., <4 g) was insensitive to the number of cycles; the 6-cycle treatment was equivalent to the 1-2-cycle treatment. For larger masses, fewer cycles yielded better results. For a 7-g tumor, the 5-cycle, 4-cycle, 3-cycle and 1-2-cycle schedules were 24%, 50%, 76%, and 84% more efficacious, respectively, than the 6-cycle schedule. The absorbed doses to kidneys, parotid glands, lacrimal glands, and red marrow were 23, 16, 70, and 1 Gy, respectively. In all fractionated schedules, the biologically effective dose to kidneys was within tolerance (<40 Gy). Conclusion: On the basis of model-derived simulations, treatment delivered in a 1-2-cycle schedule is recommended to achieve better outcomes for patients undergoing [177Lu]Lu-PSMA therapy.
引用
- Zaid NRR, Bastiaannet R, Hobbs R, et al. Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization. J Nucl Med. 2025. PMID: 39753362. doi:10.2967/jnumed.124.268457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。